Advertisement

ASCO Applauds Administration Decision to Withdraw Most Favored Nation Model

Statement by Howard A. Burris III, MD, FACP, FASCO, Board Chair of the Association for Clinical Oncology


Advertisement
Get Permission

“The Association for Clinical Oncology (ASCO) commends the Biden Administration for proposing to rescind the Most Favored Nation (MFN) model from consideration. ASCO has consistently opposed the ill-advised MFN model, as it would have had a devastating impact on people with cancer.

Howard A. Burris III, MD, FACP, FASCO

Howard A. Burris III, MD, FACP, FASCO

“The proposed MFN model would have imposed a nationwide, mandatory experiment that would cut reimbursement for 50 drugs, including 38 drugs used to treat cancer. According to estimates from the Centers for Medicare & Medicaid Services (CMS), the MFN model would have caused 19% of Medicare beneficiaries to lose access to drugs included in the model. ASCO’s analysis conducted in 2020 found that reimbursement cuts to just four drugs commonly used to treat lung and other cancers would have resulted in patients with lung cancer losing as many as 87,556 years of life due to their loss of access to these drugs over the model’s 7-year duration.

“ASCO looks forward to continuing to work collaboratively with the Administration and Congress on our shared goals of controlling the rising cost of cancer drug treatments and ensuring patient access to the highest quality cancer care.” 

© 2021. American Society of Clinical Oncology. All rights reserved.


Advertisement

Advertisement



Advertisement